The investigators plan to further develop a prototype, evidence-based, electronic clinical decision support system (CDSS) for pneumonia care (ePneumonia) with interoperability across Electronic Health Records in order to improve clinical outcomes and reduce healthcare resource utilization. The specific aims of this study are to evaluate the usability of ePneumonia adapted for Cerner and its impact on clinical, patient-centered and healthcare resource utilization outcomes in a stepped-wedge implementation study in 16 hospital emergency departments (EDs) across the Intermountain Healthcare integrated health system.
Since the launch of a paper-based pneumonia care process model in 1994, decision support for pneumonia care has been under continuous development at Intermountain. Studies published in 2001 and 2006 demonstrated decreased mortality using paper-based methods. An electronic pneumonia Clinical Decision Support System was later developed in the original Intermountain computing environment and implemented in 4 regional emergency departments (ED) in 2011. This tool featured a novel mortality predictor and real-time synthesis of clinical data to guide diagnosis, risk stratification, admission triage and guideline-concordant treatment. An outcome study published in 2015 demonstrated reduction in mortality with tool use compared to usual care. Most recently, Intermountain researchers led by study co-Investigator, Dr. Brandon Webb, developed an innovative tool to predict risk of drug-resistant bacteria and demonstrated its potential to improve antibiotic use and outcomes. The investigators have entered a robust phase of additional development and adaptation of ePneumonia into the Cerner Electronic Health Record (EHR) system. The objective of this study is to advance development of an evidence-based, electronic CDSS for pneumonia care with interoperability across EHRs in order to improve clinical outcomes and reduce healthcare resource utilization. The specific aim of this study is to evaluate the usability of ePneumonia and its associated impact on clinical, patient-centered and healthcare resource utilization outcomes in a stepped-wedge implementation study in 16 hospital EDs in the Intermountain Healthcare integrated health system. * Hypothesis #1: Healthcare providers will affirm ePneumonia usability, lack of interference with clinical workflow and only minor unintended consequences of use. * Hypothesis #2: In patients with community-onset pneumonia, ePneumonia use will improve clinical and patient-centered outcomes and decrease healthcare resource utilization. One year of baseline clinical outcome data will be gathered for all 16 emergency departments. The first of 6 clusters of ED's will begin prospective data collection in January 2018, with the remaining coming on at 2 month intervals until ePneumonia has been deployed at all sites. An additional 1 year of data collection will be continued through 2019.
Study Type
OBSERVATIONAL
Enrollment
10,000
ePneumonia clinical decision support system for community-onset pneumonia
Cassia Regional Hospital
Burley, Idaho, United States
American Fork Hospital
American Fork, Utah, United States
Cedar City Hospital
Cedar City, Utah, United States
Delta Community Hospital
Delta, Utah, United States
Fillmore Hospital
Fillmore, Utah, United States
Heber Valley Hospital
Heber City, Utah, United States
Logan Regional Hospital
Logan, Utah, United States
Sanpete Valley Hospital
Mount Pleasant, Utah, United States
Intermountain Medical Center
Murray, Utah, United States
McKay-Dee Hospital
Ogden, Utah, United States
...and 7 more locations
30 day all-cause mortality
mortality within 30 days of initial ED visit
Time frame: 30 days
Matching of patient disposition from the ED with ePneumonia recommendation
ePneumonia use will increase simple agreement between patient disposition from the ED with ePneumonia recommendation based on illness severity
Time frame: End of initial ED visit, <24 hours after ED arrival
Accuracy of Drug Resistance in Pneumonia (DRIP) score within the ePneumonia logic to predict Multi-Drug Resistant (MDR) pathogens
Sensitivity, specificity, positive and negative predictive values for DRIP score versus identified pathogens
Time frame: 30 days
Antibiotic utilization rates, in terms of appropriateness of spectrum
Antibiotic utilization rates, in terms of appropriateness of spectrum versus identified pneumonia pathogen
Time frame: 30 days
Rate of secondary hospital admission within 7 days for ED patients whose initial disposition was outpatient care
Rate of secondary hospital admission within 7 days for ED patients whose initial disposition was outpatient care
Time frame: 7 days
Direct costs
ePneumonia use will produce lower direct costs (total and variable)
Time frame: Duration of hospital stay, censored at 90 days
Length of stay
ePneumonia use will shorten length of stay measured in hours
Time frame: Duration of hospital stay, censored at 90 days
Healthcare providers will affirm ePneumonia usability, lack of interference with clinical workflow and only minor unintended consequences of use
Qualitative outcome based on provider surveys
Time frame: 3 year study duration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.